Skip to main content
SpringerLink
Log in

Prävention, Früherkennung und Behandlung von Zytostatikaparavasaten

Praktisches Management in der uroonkologischen Praxis

Prevention, early diagnosis and treatment of chemoextravasation

Practical management in the uro-oncological practice

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Zytostatikaparavasate gehören mit einer Inzidenz von 1–6% zu den bedeutsamsten iatrogenen Komplikationen in der Onkologie. Abhängig von der Substanz können diese das Gewebe schädigen oder zerstören. Eine Verzögerung der Fortsetzung der systemischen Therapie, lange Hospitalisierungen, dauerhafte Funktionseinschränkungen sowie chirurgische Interventionen können die Folge sein. Eine korrekte i. v.-Applikation ist daher für den Patienten mit Zytostatikatherapie von äußerster Wichtigkeit. Trotz einer perfekten Venenpunktion und allen Sicherheitsmaßnahmen lässt sich ein Paravasat aber nicht immer vermeiden. Diese Arbeit soll dem Urologen, der eine spezifische Chemotherapie urologischer Neoplasien anbietet, ein nützlicher Ratgeber in Prävention, in Diagnostik sowie in der Behandlung dieser gefürchteten Komplikation sein.

Abstract

Extravasation of chemotherapeutic agents is a rare (1–6%) but potentially severe iatrogenic complication of systemic therapy. Depending on the cytotoxic agent, tissue damage and necrosis may occur, followed by a delay in administration of chemotherapy, prolonged hospitalization, impaired function, and the need for tissue excision. Therefore, optimal placement of the intravenous catheter is absolutely necessary to reduce the risk of extravasation. The aim of this report is to give urologists a practical and useful guide on how to prevent, diagnose, and treat this complication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Beason R (1990) Antineoplastic vesicant extravasation. J Intraven Nurs 13:111–114

    PubMed  CAS  Google Scholar 

  2. Berghammer P, Pohnl R, Baur M, Dittrich C (2001) Docetaxel extravasation. Support Care Cancer 9:131–134

    Article  PubMed  CAS  Google Scholar 

  3. Bertelli G, Gozza A, Forno GB, Vidili MG et al (1995) Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13:2851–2855

    PubMed  CAS  Google Scholar 

  4. Boyle DM, Engelking C (1995) Vesicant extravasation: myths and realities. Oncol Nurs Forum 22:57–67

    PubMed  CAS  Google Scholar 

  5. Brincker H, Saeter G (1986) Fifty-five patient years‘ experience with a totally implanted system for intravenous chemotherapy. Cancer 57:1124–1129

    Article  PubMed  CAS  Google Scholar 

  6. Cicchetti S, Jemec B, Gault DT (2000) Two case reports of vinorelbine extravasation: management and review of the literature. Tumori 86:289–292

    PubMed  CAS  Google Scholar 

  7. Damert HG, Lenz-Scharf O, Altmann S, Schneider W (2007) Soft-tissue defects on the dorsum of the hand by extravasation of the cytostatic agents: surgical options of treatment. Handchir Mikrochir Plast Chir 39:409–413

    Article  PubMed  Google Scholar 

  8. de Wit M (2009) Zytostatikabedingte Paravasate – ein seltenes Ereignis? Onkologie 15:169–172

    Article  Google Scholar 

  9. Dorr RT (1990) Antidotes to vesicant chemotherapy extravasations. Blood Rev 4:41–60

    Article  PubMed  CAS  Google Scholar 

  10. Dorr RT, Alberts DS (1985) Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74:113–120

    PubMed  CAS  Google Scholar 

  11. Ener RA, Meglathery SB, Styler M (2004) Extravasation of systemic hemato-oncological therapies. Ann Oncol 15:858–862

    Article  PubMed  CAS  Google Scholar 

  12. Fehm TMA, Lipp HP, Schumacher K (2008) Paravasation von Zytostatika. Gynäkologe 41:607–612

    Article  Google Scholar 

  13. Garnick M (1981) Persistence of anthracycline levels following dermal and subcutaneous adriamycin extravasation (abstract). In: Magee PN, Foti M, Bergbauer P (eds) Proceedings of the American Society of Clinical Oncology. Waverly Press, Baltimore MD, pp 22–173

  14. Gaze NR (1978) Tissue necrosis caused by commonly used intravenous infusions. Lancet 2:417–419

    Article  PubMed  CAS  Google Scholar 

  15. Hastings-Tolsma M, Yucha CB (1994) IV infiltration no clear signs, no clear treatment? RN 57:34–39

    PubMed  CAS  Google Scholar 

  16. Heckler FR (1989) Current thoughts on extravasation injuries. Clin Plast Surg 16:557–563

    PubMed  CAS  Google Scholar 

  17. Ignoffo RJ, Friedman MA (1980) Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7:17–27

    Article  PubMed  CAS  Google Scholar 

  18. Iwamoto T, Hiraku Y, Okuda M, Kawanishi S (2008) Mechanism of UVA-dependent DNA damage induced by an antitumor drug dacarbazine in relation to its photogenotoxicity. Pharm Res 25:598–604

    Article  PubMed  CAS  Google Scholar 

  19. Jordan K, Grothe W, Schmoll HJ (2005) Extravasation of chemotherapeutic agents: prevention and therapy. Dtsch Med Wochenschr 130:33–37

    Article  PubMed  CAS  Google Scholar 

  20. Kassner E (2000) Evaluation and treatment of chemotherapy extravasation injuries. J Pediatr Oncol Nurs 17:135–148

    Article  PubMed  CAS  Google Scholar 

  21. Langstein HN, Duman H, Seelig D, Butler CE et al (2002) Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 49:369–374

    Article  PubMed  Google Scholar 

  22. Larson DL (1985) What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75:397–405

    Article  PubMed  CAS  Google Scholar 

  23. Loth TS (1986) Minimal surgical debridement for the treatment of chemotherapeutic agent-induced skin extravasations. Cancer Treat Rep 70:401–404

    PubMed  CAS  Google Scholar 

  24. Mader I (2001) Paravasation von Zytostatika. Springer, Berlin Heidelberg New York

  25. Mouridsen HT, Langer SW, Buter J, Eidtmann H et al (2007) Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18:546–550

    Article  PubMed  CAS  Google Scholar 

  26. Nogler-Semenitz E, Mader I, Furst-Weger P, Terkola R et al (2004) Extravasation of cytotoxic agents. Wien Klin Wochenschr 116:289–295

    Article  PubMed  Google Scholar 

  27. Olver IN, Aisner J, Hament A, Buchanan L et al (1988) A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6:1732–1735

    PubMed  CAS  Google Scholar 

  28. Rudolph R, Larson DL (1987) Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5:1116–1126

    PubMed  CAS  Google Scholar 

  29. Schulmeister L (2007) Totect: a new agent for treating anthracycline extravasation. Clin J Oncol Nurs 11:387–395

    Article  PubMed  Google Scholar 

  30. Sehested M, Jensen PB (1996) Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51:879–886

    Article  PubMed  CAS  Google Scholar 

  31. Sehouli JBC, Chekerov R, Camara O, Mustea A et al (2006) Zytostatikaextravasate - Modernes Management in der Onkologie. Onkologie 12:73–84

    Article  Google Scholar 

  32. Uges JW, Vollaard AM, Wilms EB, Brouwer RE (2006) Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane. Int J Clin Oncol 11:467–470

    Article  PubMed  Google Scholar 

  33. von Heimburg D, Pallua N (1998) Early and late treatment of iatrogenic injection damage. Chirurg 69:1378–1382

    Article  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universität Ulm, Prittwitzstraße 43, 89075, Ulm, Deutschland

    L. Rinnab, R.E. Hautmann & J. Simon

  2. Klinik für Innere Medizin III, Universität, Ulm, Deutschland

    M. Ringhoffer & R. Mayer-Steinacker

Authors
  1. L. Rinnab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ringhoffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Mayer-Steinacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R.E. Hautmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Rinnab.

Anhang

Anhang

Abb. 4
figure 4a

Dokumentationsbogen Zytostatikaparavasate (Dokumentationsbogen sollte der Patientenakte beigefügt werden)

Full size image
Abb. 4
figure 4b

Fortsetzung

Full size image

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rinnab, L., Ringhoffer, M., Mayer-Steinacker, R. et al. Prävention, Früherkennung und Behandlung von Zytostatikaparavasaten. Urologe 48, 1283–1294 (2009). https://doi.org/10.1007/s00120-009-2103-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-009-2103-4

Schlüsselwörter

Keywords

Search

Navigation